Literature DB >> 9409555

Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis.

E M Minshall1, L Cameron, F Lavigne, D Y Leung, D Hamilos, E A Garcia-Zepada, M Rothenberg, A D Luster, Q Hamid.   

Abstract

Eotaxin is an eosinophil-specific chemokine associated with the recruitment of eosinophils to the site of allergic inflammation. The aims of this study were to determine the expression of eotaxin in nasal biopsies from allergic and nonallergic individuals with chronic severe sinusitis, and to examine whether the expression of this chemokine is upregulated following allergen challenge in the nasal mucosa of patients with allergic rhinitis. We also undertook to phenotype of inflammatory cells within the submucosa expressing eotaxin mRNA. Nasal turbinate tissue from 16 individuals with allergic or nonallergic chronic sinusitis and 10 normal controls were examined for the presence of eotaxin mRNA and immunoreactivity by in situ hybridization and immunocytochemistry. The numbers of cells expressing eotaxin mRNA were also determined after either allergen or diluent challenge in atopic subjects with a history of allergic rhinitis. There was a constitutive expression of eotaxin-immunoreactivity and the presence of eotaxin mRNA-positive cells in nasal biopsies from normal individuals. Compared with normal controls, the numbers of cells expressing eotaxin mRNA and protein were significantly increased in both allergic and nonallergic sinusitis (P < 0.001). Eotaxin mRNA was expressed by nasal epithelial cells and primarily colocalized to CD68-positive macrophages within the subepithelium. In subjects with allergic rhinitis, allergen challenge markedly increased the numbers of cells expressing eotaxin mRNA and immunoreactivity in the epithelial and subepithelial cell layers (P < 0.05). This could be largely attributed to a local increase in eotaxin production within the nasal tissues. The results of this study demonstrate the constitutive expression of eotaxin and show that the numbers of cells expressing eotaxin mRNA are increased within the epithelial and subepithelial layers of the nasal mucosa in individuals with chronic sinusitis. Furthermore, allergen challenge of the nasal mucosa in atopic subjects results in a local upregulation of eotaxin expression. These data suggest a potential role for this chemokine in the pathogenesis of allergic and nonallergic eosinophilic inflammation characterizing chronic sinusitis and allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409555     DOI: 10.1165/ajrcmb.17.6.2865

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  34 in total

1.  Chemokines in the limbal form of vernal keratoconjunctivitis.

Authors:  A M Abu El-Asrar; S Struyf; S A Al-Kharashi; L Missotten; J Van Damme; K Geboes
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 2.  Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies.

Authors:  Manuel A R Ferreira
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

3.  Leukotriene Inhibitors in Sinusitis.

Authors:  John W Steinke; Joshua L Kennedy
Journal:  Curr Infect Dis Rep       Date:  2012-01-29       Impact factor: 3.725

4.  Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polyps.

Authors:  Julie A Poposki; Ashraf Uzzaman; Deepti R Nagarkar; Regina T Chustz; Anju T Peters; Lydia A Suh; Roderick Carter; James Norton; Kathleen E Harris; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

Review 5.  Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis.

Authors:  Seema S Aceves; Steven J Ackerman
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

6.  Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.

Authors:  John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-06-24       Impact factor: 10.793

Review 7.  The Role of Allergic Rhinitis in Chronic Rhinosinusitis.

Authors:  Samuel N Helman; Emily Barrow; Thomas Edwards; John M DelGaudio; Joshua M Levy; Sarah K Wise
Journal:  Immunol Allergy Clin North Am       Date:  2020-01-14       Impact factor: 3.479

Review 8.  Rhinosinusitis: Establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  Otolaryngol Head Neck Surg       Date:  2004-12       Impact factor: 3.497

Review 9.  Antileukotrienes in upper airway inflammatory diseases.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Kagan Ipci; Ethem Şahin
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

Review 10.  Rhinosinusitis: establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  J Allergy Clin Immunol       Date:  2004-12       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.